SCHEMBL2857675

SCHEMBL2857675

Cc1cccc(Oc2cccc(C(=O)O)c2)c1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.73
KMO O15229 1/20 0.61
KDM4E B2RXH2 1/20 0.56
NPC1 O15118 1/20 0.56
POLB P06746 1/20 0.56
CYP2C9 P11712 1/20 0.56
RAB9A P51151 1/20 0.56
PPARG P37231 1/20 0.56
KMT2A Q03164 2/20 0.54
GFER P55789 2/20 0.54
LMNA P02545 1/20 0.53
MRGPRX4 Q96LA9 1/20 0.53
HSD17B1 P14061 1/20 0.52
HSD17B2 P37059 1/20 0.52
MAPK1 P28482 1/20 0.52
GCK P35557 1/20 0.52
ALDH1A1 P00352 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9133630 0.91 AKR1C3 (0.71) AKR1C3KMOKDM4ENPC1POLB
SCHEMBL68858 0.89 AKR1C3 (0.92) AKR1C3KMOKDM4ENPC1POLB
SCHEMBL30307454 0.89 AKR1C3 (0.92) AKR1C3KMOKDM4ENPC1POLB
SCHEMBL30449599 0.89 AKR1C3 (0.92) AKR1C3KMOKDM4ENPC1POLB
SCHEMBL15013520 0.88 HSD17B1 (0.62) AKR1C3KMOKDM4EKMT2AGFER
SCHEMBL2867826 0.88 AKR1C3 (0.77) AKR1C3KMOKDM4ENPC1POLB
SCHEMBL1635565 0.87 AKR1C3 (0.88) AKR1C3KMOKDM4ENPC1POLB
SCHEMBL30266792 0.87 AKR1C3 (0.88) AKR1C3KMOKDM4ENPC1POLB
SCHEMBL27414056 0.86 AKR1C3 (0.74) AKR1C3KMOKDM4ENPC1POLB
SCHEMBL1042631 0.85 AKR1C3 (0.92) AKR1C3KMOKDM4ENPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230195003-A1 ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS FUJIFILM BUSINESS INNOVATION CORP. (JP) 2023-06-22 US disclosed
EP-2651888-B1 N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders UNIV LEUVEN KATH (BE) 2017-05-17 EP disclosed
US-9266832-B2 Compounds for the treatment of neurodegenerative diseases Katholieke Universiteit Levun (BE) 2016-02-23 US disclosed
US-20130295261-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS SENOMYX, INC. (US) 2013-11-07 US disclosed
EP-2651888-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 EP disclosed
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-17 US disclosed
US-8420145-B2 Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers SENOMYX, INC. (US) 2013-04-16 US disclosed
WO-2012080221-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 WO disclosed
EP-2254891-A2 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS Senomyx, Inc. (US) 2010-12-01 EP disclosed
WO-2009111447-A2 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS SENOMYX, INC. (US) 2009-09-11 WO disclosed
US-20090220662-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS SENOMYX, INC. 2009-09-03 US disclosed
EP-0757702-A1 POLY (IMIDE-ETHERS) E.I. DU PONT DE NEMOURS AND COMPANY (US) 1997-02-12 EP disclosed
WO-1995029948-A1 POLY (IMIDE-ETHERS) E.I. DU PONT DE NEMOURS AND COMPANY (US) 1995-11-09 WO disclosed
EP-0425134-A1 Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 AKR1C3 1608/4885KMO 3395/4885KDM4E 2195/4885
US-20090220662-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS TAS2R10, TAS2R41, TAS2R30 AKR1C3 3307/4885KMO 4172/4885KDM4E 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.